Biosimulation Market
                     Biosimulation
Market
Global Forecast to 2022
Biosimulation
Market is expected to reach 
$ 2.88 Billion by 2022
Growing at a 
CAGR of  XX% (2017 – 2022)
Biosimulation Market
is expected to reach USD 2.88 Billion by 2022 from USD 1.38 
Billion in 2017, at a CAGR of 15.9%. The growth of this market is 
majorly driven by factors such as the increase in R&D investments 
in the pharmaceutical and biotechnology industries, growing 
adoption of biosimulation software by regulatory bodies, 
technologically advanced QSP systems, need to curtail drug 
discovery and development costs, and growth in the biologics and 
biosimilars markets.
 
The biosimulation market is expected to reach USD 2.88 Billion by 
2022 from USD 1.38 Billion in 2017, at a CAGR of 15.9%.
Major Key Player
Simulations Plus (US)
Physiomics (UK) 
Evidera (US) 
Schrödinger (US)
Dassault Systèmes (France)
Rosa (US)
Nuventra Pharma (US)
North America to dominate the biosimulation market
In 2017, North America is expected to dominate the market 
followed by Europe. The large share of this geographical 
segment is attributed to factors such as growth in the 
biotechnology and pharmaceutical industry, a large number of 
ongoing drug development processes, increased use of 
personalized medicine, and increasing R&D expenditure by 
pharmaceutical and biotechnology companies.